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The Docking Stage of Yeast Vacuole Fusion Requires the Transfer of 
Proteins from a cis-SNARE Complex to a Rab/Ypt Protein
 
Albert Price, Darren Seals, William Wickner, and Christian Ungermann
 
Department of Biochemistry, Dartmouth Medical School, Hanover, New Hampshire 03755-3844
 
Abstract. 
 
The homotypic fusion of yeast vacuoles re-
quires Sec18p (NSF)-driven priming to allow vacuole 
docking, but the mechanism that links priming and 
docking is unknown. We find that a large multisubunit 
protein called the Vam2/6p complex is bound to cis-
paired SNAP receptors (SNAREs) on isolated vacu-
oles. This association of the Vam2/6p complex with the 
cis-SNARE complex is disrupted during priming. The 
Vam2/6p complex then binds to Ypt7p, a guanosine 
triphosphate binding protein of the Rab family, to ini-
tiate productive contact between vacuoles. Thus, cis-
SNARE complexes can contain Rab/Ypt effectors, and 
these effectors can be mobilized by NSF/Sec18p-driven 
priming, allowing their direct association with a
Rab/Ypt protein to activate docking.
Key words: Vps39/Vam6p • Vps41/Vam2p • Ypt7p • 
priming • Rab/Ypt effector
 
Introduction
 
Regulated fusion of organelle membranes (Rothman,
1994) is essential for subcellular protein compartmenta-
tion. The protein and lipid factors that catalyze membrane
fusion are being identified and their functional relation-
ships are receiving intense study. Each fusion reaction
seems to require integral membrane proteins termed
SNAP receptors (SNAREs)
 
1
 
 (Pfeffer, 1996), which func-
tion through the association of their cytoplasmic domains
to form coiled-coils. Associated SNAREs, whether in cis
(on the same membrane) or in trans (attached to apposed
membranes), can be disassembled by the action of the
ATP-driven chaperone, 
 
N
 
-ethylmaleimide sensitive factor
(NSF)/Sec18p, and its cochaperone 
 
a
 
SNAP/Sec17p (Söll-
ner et al., 1993; Hanson et al., 1995; Ungermann et al.,
1998a). SNARE associations are regulated either directly
or indirectly by members of the Rab/Ypt family of GTP-
ases and their associated proteins, termed Rab/Ypt effec-
tors (McBride et al., 1999; Carr et al., 1999; Ungermann
et al., 1998a). In several systems, Rab/Ypt proteins and
their effectors have been shown to mediate a SNARE-
independent initial association of membranes, termed teth-
ering, which is the first step of the docking stage (Cao et al.,
1998; Ungermann et al., 1998b). Tethering is a necessary
prelude to trans-SNARE pairing, which establishes a sta-
bly docked organelle pair. The recent finding (McBride et
al., 1999) that Rab effectors can directly associate with
SNAREs and that this association can be modulated by
the chaperone NSF, suggested that these Rab effectors
may directly mediate trans-SNARE pairing and the subse-
quent steps that lead to fusion.
We have studied the homotypic fusion of yeast vacuoles.
This reaction occurs in obligately ordered subreactions of
priming, docking, and fusion. Five SNAREs on the puri-
fied organelle are found in a cis complex with the chaper-
ones Sec18p, Sec17p, and low molecular weight activity #1
(LMA1) (Ungermann et al., 1999). This complex has been
viewed as simply the remains of SNARE associations from
prior fusion events, though current studies reported below
show that it actually has a greater complexity and distinct
functions. The cis-SNARE complex is disassembled as
Sec18p hydrolyzes ATP during priming (Barnard et al.,
1997; Ungermann et al., 1998b). This priming event is nec-
essary for docking (Mayer and Wickner, 1997). Docking
occurs in two stages, a reversible vacuole association
termed tethering, which depends on the Rab-like GTPase
Ypt7p, and the subsequent pairing of SNAREs in trans
(Ungermann et al., 1998a). We report that Vam2/Vps41p
and Vam6/Vps39p, identified in vacuole protein sorting
(vps) screens for defective vacuole protein sorting (Stack
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N
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et al., 1995) and in vacuole morphology (vam) screens for
fragmented vacuole morphology (Wada et al., 1992), are
also required for vacuole docking (Price et al., 2000).
Docking triggers a brief release of calcium from the vacu-
ole lumen (Peters and Mayer, 1998) which leads to vacu-
ole association of a complex of calmodulin and protein
phosphatase 1 (Peters et al., 1999), a dephosphorylation of
a vacuolar target protein(s), release of the LMA1 cochap-
erone (Xu et al., 1998), and membrane fusion.
Despite this progress in defining the components
that catalyze each stage of the reaction, the mechanism
whereby the different stages are coupled is unknown. One
of the most intriguing questions is how the priming of vac-
uoles leads to their docking. Specifically, how does the
disassembly of the cis-SNARE complex lead to the Ypt7p-
dependent association of vacuoles, and what are the link-
ing proteins? We now show that this function is fulfilled by
a protein complex that contains Vam2/Vps41p and Vam6/
Vps39p, termed Vam2/6p, working as a vacuolar Rab/Ypt
effector. Vam2p and Vam6p are localized to the vacuole
as part of a large complex (Nakamura et al., 1997) that is
required for the docking stage of homotypic vacuole fu-
sion (Price et al., 2000). However, unlike other known
Rab/Ypt effectors, Vam2/6p is initially bound to the cis-
SNARE complex and is released from the SNAREs upon
Sec18p-dependent priming. Vam2/6p can only then bind
to Ypt7p to initiate docking, providing an important physi-
cal and functional link between membrane priming and
docking.
 
Materials and Methods
 
Biochemical Reagents
 
Gdi1p was purified according to Haas et al. (1995). All inhibitors and anti-
bodies were dissolved or dialyzed in PS buffer (20 mM Pipes-KOH, pH
6.8, 200 mM sorbitol) unless stated otherwise.
 
Antibody Production and Purification
 
Antibodies against the Vam2 and Vam6 proteins were prepared as de-
scribed in Price et al. (2000).
 
Assay for Release of Vam2/Vam6p
 
Vacuoles from 
 
S. cerevisiae
 
 BJ3505 (wild-type or with hemagglutinin
[HA]-tagged Vam6p) were incubated under standard fusion reaction con-
ditions for 0–90 min. The reactions were then diluted fivefold with PS
buffer and the vacuoles sedimented by centrifugation (14,000 
 
g
 
, 5 min,
4
 
8
 
C). Proteins in the supernatant were precipitated by the addition of
TCA to a final concentration of 15% (vol/vol), washed with ice-cold ace-
tone, and analyzed by SDS-PAGE and immunoblotting.
For some experiments, the chromosomal 
 
VAM6
 
 gene was replaced
with a HA epitope–tagged version of the 
 
VAM6
 
 gene by recombination
with a plasmid cassette containing the HA-tagged 
 
VAM6
 
 gene. A 1.2-Kb
Kpn1-EcoRI fragment of the 
 
VAM6
 
 gene containing six copies of the HA
epitope at the 5
 
9
 
 end of the coding sequence (a gift from Dr. Yoh Wada,
Osaka University, Osaka, Japan) was cloned into pRS306. This construct
was then linearized at the MscI site in the 
 
VAM6
 
 coding sequence and
transformed into 
 
S. cerevisiae
 
 BJ3505. Transformants were analyzed for ex-
pression of HA-Vam6p by SDS-PAGE followed by immunoblotting with
the anti-HA mAb 12CA5 (Boehringer) and antiserum against Vam6 pro-
tein. HA-tagged 
 
VAM6
 
 rescues the fragmented vacuole phenotype of
 
vam6
 
D
 
 yeast (Nakamura et al., 1997), and fusion of HA-Vam6p vacuoles in
vitro is indistinguishable from that of wild-type vacuoles (data not shown).
 
Immunoprecipitations
 
Anti-Vam2p, anti-Ypt7p, and anti-Vam3p were cross-linked to protein
A–Sepharose CL-4B (Amersham Pharmacia Biotech) using dimethylpi-
melimidate (Harlowe and Lane, 1988). Vacuoles (100 mg) were solubilized in
200 
 
m
 
l of solubilization buffer (20 mM Hepes-KOH, pH 7.4, 150 mM NaCl,
10% [wt/vol] glycerol, 1% [vol/vol] Triton X-100) with protease inhibitor
cocktail (Haas, 1995) for 10 min on ice. Insoluble material was removed by
centrifugation (14,000 
 
g
 
, 10 min, 4
 
8
 
C). The supernatant was then incubated
with protein A–Sepharose immobilized antibodies for 2 h at 4
 
8
 
C in a final
volume of 500 
 
m
 
l of solubilization buffer. The beads were washed twice with
solubilization buffer and bound proteins were eluted with 0.1 M glycine, pH
2.5. The eluates were then neutralized by the addition of 0.1 M Tris-HCl,
pH 9.0, and analyzed by SDS-PAGE and immunoblotting.
 
Sucrose Velocity Gradients
 
Vacuoles were sedimented (14,000 
 
g
 
, 10 min, 4
 
8
 
C) and solubilized for 10
min on ice in PS solubilization buffer, which is PS buffer containing 1%
(vol/vol) Triton X-100 and protease inhibitor cocktail (Haas, 1995). Insol-
uble material was removed by sedimentation (14,000 
 
g
 
, 10 min, 4
 
8
 
C). The
vacuole extract was layered onto a 12-ml gradient of 10–40% (wt/vol) su-
crose in PS buffer with 1% (vol/vol) Triton X-100 and centrifuged (38,000
rpm, 6 h, 4
 
8
 
C; Beckman SW-41 rotor). Fractions were analyzed by SDS-
PAGE followed by immunoblotting. BSA (4S), 
 
a
 
2-macroglobulin (20S),
and ferritin (65S) were centrifuged in a parallel gradient and analyzed by
SDS-PAGE and staining with Coomassie brilliant blue.
 
Results
 
Association of Vam2/6p with SNAREs
 
In accord with earlier studies (Nakamura et al., 1997),
Vam2p and Vam6p are associated with each other as part
of a large complex, as assayed in Triton X-100 extracts of
vacuoles by coimmunoprecipitation (Fig. 1 A, lane 2) and
cosedimentation at 65S in sucrose velocity gradients (Fig.
1 B). Gradient fractions were also assayed for the SNARE
proteins Nyv1p and Vam3p. Surprisingly, although the cis-
SNARE complex (Ungermann et al., 1999) was labile un-
der these conditions, a small fraction of these SNAREs
cosedimented with Vam2/6p (Fig. 1 B). This was con-
firmed directly by observing a coimmunoprecipitation of
Vam2p by anti-Vam3p (Fig. 2 A, lane 1), but not by con-
trol IgG (Fig. 2 A, lane 4). This association was seen with
other members of the SNARE complex, as antibody to the
v-SNAREs Vti1p or Ykt6p immunoprecipitate Vam2p
(Fig. 2 B, lanes 2 and 3) at least as efficiently as does anti-
body to Vam3p (Fig. 2 B, lane 1).
Vacuole cis-SNARE complexes are dissociated by the
priming activity of Sec18p (Ungermann et al., 1999). We
find that Vam2/6p is released from its association with the
cis-SNARE complex during priming. Coimmunoprecipita-
tion of Vam2p with Vam3p is diminished 77% upon incu-
bation at 27
 
8
 
C with ATP (Fig. 2 A, lane 2), and this release
is completely blocked by antibody to the priming catalyst
Sec18p (Fig. 2 A, lane 3) but not by ligands that block
steps other than priming (data not shown). Not only do
SNAREs cosediment (Fig. 1 B) and coimmunoprecipitate
(Fig. 2, A and B) with Vam2/6p, but disruption of the cis-
SNARE complex through priming the vacuoles (Fig. 3)
causes a shift of the 65S Vam2/6p to a slower sedimenting
species of 38S. As Vam2/6p is a peripheral membrane
complex (Nakamura et al., 1997), this loss of its association
with integral membrane SNAREs, as well as its involve-
ment in the docking reaction (Price et al., 2000), raises the
question of the identity of its subsequent physical and
functional associations on the vacuole membrane.
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Vam2/6p Physically Associates with Ypt7p
after Priming
 
Since both Vam2/6p and Ypt7p are essential for docking
(Mayer and Wickner, 1997; Price et al., 2000), we asked
whether Vam2/6p and Ypt7p are directly associated. We
find that antibody to Ypt7p will cross-immunoprecipitate
 
z
 
13% of the Vam6p from vacuole detergent extracts (Fig.
4 A). Moreover, the GTP form of purified recombinant
glutathione 
 
S
 
-transferase (GST)–Ypt7p will bind the com-
plex containing Vam6p (Fig. 4 B, lane 3) and Vam2p (data
not shown) from the 38S gradient-purified fractions (Fig.
3) of Vam2/6p complex from primed vacuoles. This associ-
ation is specific for the nucleotide (Fig. 4 B, lanes 2–4) and
is not seen with the GTP form of the fusion protein of
GST with Ypt1p (Fig. 4 B, lane 5), a closely related Rap/
Ypt protein required for ER to Golgi traffic. Without
priming, the 65S Vam2/6p complex (Fig. 4 B, lane 6) does
not associate with GST–Ypt7p:GTP
 
g
 
S (Fig. 4 B, lane 8)
above background levels (Fig. 4 B, lanes 7–10). These re-
sults indicate that the Vam2/6p complex acquires a direct
affinity for Ypt7p after priming and establish that Vam2/
6p is an important Ypt7p effector.
 
Ypt7p Regulates the Localization of Vam2/6p to
the Vacuole
 
To investigate whether Vam2p and Vam6p also interact
Figure 1. Physical associations of Vam2p and Vam6p. (A)
Vam2p and Vam6p form a stable complex. BJ3505 HA-Vam6p
vacuoles were solubilized with buffer containing 1% Triton
X-100 or incubated at 278C in a complete fusion reaction contain-
ing Gdi1p (64 mg/ml) for 90 min. Detergent extracts and release
reaction supernatants were immunoprecipitated with antibody
against Vam2p or preimmune antibody as described in Materials
and Methods. Immunoprecipitates were analyzed by SDS-PAGE
and immunoblotting with anti-HA mAb 12CA5. (B) Sucrose
velocity gradients. BJ3505 vacuoles (500 mg) were solubilized in
400 ml of PS solubilization buffer and analyzed on 10–40% su-
crose gradients as described in Materials and Methods. Gradient
fractions were analyzed by SDS-PAGE and immunoblotting with
antisera against Vam2p, Vam6p, Nyv1p, and Vam3p. Immuno-
blots were then quantified by scanning densitometry and plotted
as a percent of the maximum signal in the peak fraction.
Figure 2. Vam2/6p is associated with the cis-SNARE complex.
(A) Association of Vam2p with Vam3p. BJ3505 vacuoles were
incubated in 103 scale fusion reactions at 278C for 10 min with or
without ATP. Lane 3 was supplemented with antibody to Sec18p.
Vacuoles were solubilized in buffer containing 1% Triton X-100
as described in Materials and Methods, and proteins immunopre-
cipitated from the detergent extracts with antibody to Vam3p.
Immunoprecipitates were analyzed by SDS-PAGE and immuno-
blotting with antisera to the indicated vacuolar proteins. (B)
Vam2p is associated with Vti1p and Ytk6p. An immunoblot of
vacuole protein immunoprecipitates from Ungermann et al.
(1999) was probed with antibody to Vam2p.
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with Ypt7p in the cell, we examined the localization of
Vam6p in a 
 
ypt
 
7
 
D
 
 strain. Purified vacuoles that lack Ypt7p
had very little Vam6p (Fig. 5, lane 4) in comparison with
wild-type vacuoles (Fig. 5, lane 3), whereas the amount of
the vacuole marker Pho8p is unaffected by the 
 
ypt7
 
D
 
 mu-
tation. The amount of Vam6p is unchanged in whole cell
lysates of 
 
ypt7
 
D
 
 cells in comparison with wild-type (Fig. 5,
lanes 1 and 2). Therefore, the 
 
ypt7
 
D
 
 mutation affects the
vacuolar localization of Vam6p but not its expression, in-
dicating a functional relationship between these compo-
nents. In contrast, the amount of Ypt7p on the vacuoles is
unaffected by the 
 
vam2
 
D
 
 and 
 
vam6
 
D
 
 mutations (see Fig. 2
of Price et al., 2000, this issue), indicating that Ypt7p has a
primary role in vacuolar localization and that Vam2p and
Vam6p are dependent on Ypt7p.
In accord with Ypt7p being required for the vacuolar lo-
calization of Vam6p in vivo, extraction of Ypt7p or inhibi-
tion of its function in vitro releases Vam2 and Vam6 pro-
teins from the vacuole membrane. When vacuoles are
incubated under standard fusion conditions, 
 
,
 
1% of
Vam2 or Vam6 protein is released into the reaction super-
natant after sedimentation (Fig. 6 A, lane 2; supernatant of
a standard fusion reaction). Vam2/6p release is strikingly
enhanced by the addition of yeast Gdi1p (Sec19p), an in-
hibitor of Rab GTPases that binds and extracts the GDP-
bound form of these proteins from membranes (Novick
and Zerial, 1997). As seen in Fig. 6 A, lane 4, the 22% of
Vam2p and Vam6p that was released from the vacuoles
upon Ypt7p release by Gdi1p is recovered in the reaction
supernatant. The integral membrane protein Pho8p is not
found in any of the reaction supernatants, indicating that
the appearance of Vam2p and Vam6p in the supernatant
is not due to fragmentation of the vacuoles. The Vam6p
that is extracted by Gdi1p is still coimmunoprecipitated by
anti-Vam2p (Fig. 1 A, lane 4), although the extracted com-
plex sediments more slowly than Vam2/6p in association
with the cis-SNAREs (data not shown). Thus, Vam2p and
Vam6p remain together throughout priming and extrac-
tion by loss of their Ypt7p anchor. We also observed that
some Vam2p is covalently modified upon release and mi-
Figure 3. Vacuole priming dissociates the Vam2/6p complex.
BJ3505 wild-type vacuoles (300 mg) were incubated at 278C for
10 min with or without Mg21/ATP in standard fusion reactions.
Vacuoles were then sedimented, solubilized in PS buffer contain-
ing 1% Triton X-100, and analyzed on sucrose velocity gradients
as in Fig. 1.
Figure 4. Association of Vam2/6p with Ypt7p. A. Vam6p is asso-
ciated with Ypt7p on isolated vacuoles. BJ3505 HA-Vam6p vacu-
oles were solubilized in buffer containing 1% Triton X-100 as
described in Materials and Methods, and proteins were immuno-
precipitated from the detergent extracts with preimmune serum
or antiserum to Ypt7p. Immunoprecipitates were analyzed by
SDS-PAGE and immunoblotting with anti-HA mAb 12CA5 and
anti-Ypt7p. (B) The 38S Vam2/6p complex binds to GST–Ypt7p:
GTPgS. BJ3505 vacuoles (650 mg) were sedimented (13,000 rpm,
10 min, 48C; Microfuge, then incubated in a 1003 scale fusion re-
action (Haas, 1995) with salt adjustment buffer for 10 min at
278C. Primed vacuoles were then sedimented as above and resus-
pended twice in 1 ml PS buffer followed by sedimentation. Primed
vacuoles, as well as a separate aliquot of unprimed vacuoles (650
mg), which had also been sedimented and resuspended, were solu-
bilized in 650 ml PS solubilization buffer and fractionated on su-
crose gradients as described in Materials and Methods. Vam2/6p
peak fractions from unprimed (65S) and primed (38S) vacuoles
(see Fig. 3) were brought to final concentration of 150 mM NaCl,
10% glycerol, and 13 protease inhibitor cocktail (Haas, 1995),
and incubated for 2 h at 48C in the presence of 12 mg of glu-
tathione–Sepharose-bound GST–Ypt7p or GST–Ypt1p. (Fusion
protein preparation: The fusion proteins were preincubated in PS
solubilization buffer containing 2 M NaCl, 10% glycerol, 1 mM
DTT, 20 mM EDTA, and 5 mM GDP [PS elution buffer] for 20
min at room temperature with 40 ml (packed volume) glu-
tathione–Sepharose 4B beads [Amersham Pharmacia Biotech].
Beads were sedimented [1 min, 13,000 rpm, 48C] and resuspended
four times as above in 1 ml of PS solubilization buffer containing
150 mM NaCl and 10% glycerol, then incubated in 25 ml of 1.23
PS buffer containing 36 mM TrisCl, pH 8.0, 180 mM KCl, 0.6 mM
MnCl2, 6 mM MgCl2, 0.13 protease inhibitor cocktail, 1 mM
DTT, and either 4 mM GTPgS, 4 mM GDP, or no nucleotide [2]
for 30 min at 278C). After the incubation of peak fractions and fu-
sion protein beads, beads were collected and suspended twice in 1
ml PS solubilization buffer. Bound proteins were eluted with 500
ml PS elution buffer for 15 min at room temperature and sepa-
rated from the beads by sedimentation as above. The elutate was
TCA-precipitated, the precipitate suspended in 1 ml 80% acetone
and collected by sedimentation, and analyzed by SDS-PAGE and
immunoblotting with antisera to Vam6p and Vam3p.
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grates at a slightly lower mobility, though the nature of
this modification and its significance have not yet been de-
termined. The removal of Ypt7p from the vacuole by
Gdi1p is dose-dependent and there is a corresponding re-
lease of Vam6p (data not shown). However, measurement
of release as a function of reaction time shows that Ypt7p
is removed very rapidly from the vacuoles by Gdi1p,
whereas the loss of Vam6p occurs gradually (Fig. 6 B).
Ypt7p is specifically required for the retention of Vam6p
on the vacuole, since addition of inhibitory anti-Ypt7p IgG
(Haas et al., 1995) causes 27% release of Vam6p (Fig. 6 A,
lane 6), and is thus as effective as Gdi1p in releasing
Vam6p, whereas preimmune IgG has no effect (Fig. 6 A,
lane 8). However, unlike Gdi1p, anti-Ypt7p does not re-
move Ypt7p from the vacuole membrane (Fig. 6 A, lanes 5
and 6). Therefore, it is the loss of full Ypt7p function and
not its removal from the vacuole membrane that causes re-
lease of the Vam2 and Vam6 proteins.
Although ATP is not required for the extraction of
Ypt7p by Gdi1p, ATP is required for the release of Vam2p
and Vam6p by either Gdi1p or anti-Ypt7 (Fig. 6 A, lanes
2–6). To determine whether ATP is needed at the same
time as Gdi1p to promote Vam2/6p release, a two-stage
reaction was performed. Vacuoles were first incubated
with Gdi1p to remove Ypt7p, then reisolated to remove
the Gdi1p. The vacuoles were then incubated with or with-
out ATP and sedimented to allow assay of released
Vam6p (Fig. 6 C). ATP alone in the second incubation is
sufficient to extract Vam6p after Gdi1p treatment in the
first incubation (Fig. 6 C, lane 4). However, whereas com-
plete release of Ypt7p is achieved in the absence of ATP
in the first 10-min incubation (Fig. 6 C, lane 3), little
Vam6p is removed in this short incubation even when
both Gdi1p and ATP are present (Fig. 6 C, lane 5). There-
fore, the ATP requirement for the release of Vam6p can-
not be simply due to effects it might have on Ypt7p, and
may not simply reflect a need for priming, which is usually
complete by 10 min (Mayer et al., 1996; Price et al., accom-
panying manuscript). The role of ATP in Gdi1p-mediated
release of Vam2/6p remains to be determined.
 
Sec18-primed Vacuoles must Dock to Retain the
Vam2/6 Complex
 
Since Ypt7p supports vacuole docking (Mayer and Wick-
Figure 5. Vam6p is lost from the vacuole in ypt7D cells. BJ3505
wild-type and ypt7D cultures (1 l) were grown to mid-log phase.
Portions (50 ml) of each were centrifuged and the cells were re-
suspended in buffer containing 2% (vol/vol) Triton X-100, 1%
(wt/vol) SDS, 0.1 M NaCl, 1 mM EDTA, 1 mM PMSF, and 10 mM
TrisCl, pH 8.0. Cells were broken by vortexing in the presence of
acid-washed glass beads. Glass beads and cell debris were re-
moved by centrifugation (48C, 1 min, 14,000 g). The remainder of
the culture was used for vacuole purification (see Materials and
Methods). Lysed cell supernatant from equivalent amounts of
cells or equivalent amounts of vacuolar protein (15 mg) were ana-
lyzed by SDS-PAGE and immunoblotting with antisera against
Vam6p and Pho8p.
Figure 6. Release of Vam2/6p from the vacuole. (A) Vam2/6p
release. BJ3505 HA-Vam6p vacuoles (see Materials and Meth-
ods) were incubated under standard fusion conditions with or
without ATP at 278C. Reactions were supplemented with control
buffer, Gdi1p (64 mg/ml), IgG against Ypt7p, or preimmune IgG.
After 90 min, the reactions were diluted fivefold with PS buffer
and the vacuoles sedimented (5 min, 14,000 g, 48C). The superna-
tants were then TCA-precipitated and analyzed by SDS-PAGE
and immunoblotting with anti-HA mAb 12CA5 or antisera
against Vam2p, Ypt7p, and Pho8p. Lanes 5–8 of the Vam2p
panel were omitted because the immunoblot of Vam2p is ob-
scured by the rabbit IgG added to the reactions. (B) Vam6p is re-
leased from the vacuole after the release of Ypt7p. BJ3505 vacu-
oles were incubated under standard fusion conditions with ATP
at 278C in the presence of Gdi1p (64 mg/ml). At the indicated
times, reactions were placed on ice. After sedimenting as above,
supernatants were analyzed by SDS-PAGE and immunoblotting
with antibodies to Vam6p and Ypt7p. (C) The ATP requirement
for Vam6p release is unrelated to the release of Ypt7p. BJ3505
vacuoles were incubated at 278C for 10 min with ATP and/or
Gdi1p (64 mg/ml) as indicated. The reactions were then diluted
10-fold with PS buffer and the vacuoles reisolated to remove
ATP and Gdi1p. Vacuoles were then resuspended in reaction
buffer with or without ATP as indicated and incubated at 278C
for an additional 80 min. Reactions were then analyzed for re-
lease of Vam6p and Ypt7p as above.
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ner, 1997; Ungermann et al., 1998b), we asked whether
inhibition of docking itself would influence Vam2/6p
localization. 20-fold dilution of the vacuoles, a non-
pharmacological treatment that prevents vacuole docking
(Mayer and Wickner, 1997), promotes Vam6p release
from the vacuoles (Fig. 7, lane 4). Like the Vam6p release
promoted by Ypt7p inhibitors, ATP is required for Vam6p
release upon dilution (Fig. 7, lane 3 vs. lane 4). Dilution
does not cause release of Ypt7p (data not shown). This
Vam6p release requires the normal priming action of
Sec18p, as addition of anti-Sec18p blocks Vam6p release
upon dilution of the fusion reaction (Fig. 7, lane 5),
whereas preimmune IgG had no effect (Fig. 7, lane 7). The
anti-Sec18p blockage of this reaction was relieved by the
addition of excess Sec18 protein (Fig. 7, lane 6), demon-
strating that the effect of the antibody and the promotion
of Vam6p release is specifically due to the activity of
Sec18p. Therefore, after priming releases Vam2/6p from
its association with the cis-SNARE complex, vacuole
docking must occur to avoid Vam2/6p release.
 
Discussion
 
Our current studies suggest a working model (Fig. 8) of
how Vam2/6p links priming and docking. In this model,
Sec18p-dependent priming releases Vam2/6p from its as-
sociation with the cis-SNARE complex (Fig. 8 A), freeing
it to interact with Ypt7p (Fig. 8 B) and other docking com-
ponents. After priming, Vam2/6p is needed for docking
(Fig. 8 C) and docking is needed for the continued vacuole
association of Vam2/6p (Figs. 5–7), suggesting that Vam2/6p
is at the docking site (Fig. 8 C). Since Vam2/6p is required
on both partner vacuoles (Price et al., 2000), Vam2/6p
complexes from apposing vacuoles may contact one an-
other during docking, although their function may also re-
quire other associated proteins. Vam2/6p may promote
trans-SNARE pairing (Fig. 8 D) largely through working
together with Ypt7p to mediate tethering. In this model,
Vam2/6p regulates docking through its cycle of associa-
tions. It remains on the vacuole in vivo and during stan-
dard fusion reactions, yet after priming, even dilution is
sufficient to cause its release. The inability of Ypt7p,
which is not released upon dilution, to anchor Vam2/6p to
diluted primed vacuoles suggests that Vam2/6p is directly
involved in trans interactions.
Each aspect of this model (Fig. 8) is supported by our
current studies. Vam2/6p is initially in a complex with
SNAREs, as judged by cosedimentation (Fig. 1 B) and
coimmunoprecipitation (Fig. 2). We find that priming, as it
frees Vam2/6p from its association with SNAREs (Fig. 2
A), releases a 38S subcomplex (Fig. 3), which has gained
an ability to associate with Ypt7p that was not seen before
priming (Fig. 4 B). Functional in vitro studies are in com-
plete accord with the transfer of Vam2/6p from association
with SNAREs to Ypt7p, as Vam2/6p does not complete its
function until docking (Price et al., 2000) and extraction of
Ypt7p by Gdi1p, or its inhibition by anti-Ypt7p disrupts
the vacuole association of Vam2/6p (Fig. 6). Finally, the
Figure 7. Sec18-primed vacuoles must dock to retain Vam6p.
BJ3505 HA-Vam6p vacuoles were incubated with or without
ATP with control buffer, antibody against Sec18p, or preimmune
IgG on ice for 10 min. Lane 6 was supplemented with Sec18 pro-
tein (100 mg/ml). Lane 2 received Gdi1p (64 mg/ml). Lanes 3–7
were then diluted 20-fold with reaction buffer with ATP where
indicated. All reactions were then incubated at 278C for 90 min
and analyzed for HA-Vam6p release.
Figure 8. Working model for the coupling of vacuolar priming,
docking, and trans-SNARE pairing. v, t, and s symbolize the
v-SNAREs (Nyv1p, Vti1p, and Ykt6p), the t-SNARE Vam3p,
and the SNAP-25 homologue Vam7p, respectively. Y7, Ypt7p;
2/6, Vam2/6 complex. See text for details.
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absence of Ypt7p due to the deletion of its gene leads to a
loss of Vam2/6p from the vacuole fraction (Fig. 5).
The 38S Vam2/6p complex from primed vacuoles will
bind to GST–Ypt7p:GTP
 
g
 
S, as judged by recovery of
Vam2p and Vam6p from the bound fraction (Fig. 4).
Though little of the endogenous Ypt7p cosediments with
Vam2/6p at 38S (data not shown), this may reflect a lim-
ited binding affinity and high dilution during purification
that is overcome in experiments that employ glutathione–
Sepharose beads with high levels of bound recombinant
GST–Ypt7p. Recent studies (Seals, D., G. Eitzen, W.
Wickner, and A. Price, manuscript in preparation) have
shown that this bound complex, and the 65S and 38S com-
plexes from which it derives, also include the four class
C VPS proteins, Vps11p, Vps16p, Vps18p, and Vps33p.
However, we cannot infer from these data which subunit
or subunits of the 38S complex directly interact with
Ypt7p, and which are only associated because they are
part of the complex but perform Rab/Ypt effector func-
tions. Further studies will be required to determine these
functional distinctions.
Our current findings and the model that they suggest
have several novel aspects. The cis-SNARE complex is
seen to not just be a left-over from trans-SNARE com-
plexes after membrane fusion is completed, but rather is
embedded in a 65S complex, which has a vital signaling
role, mediated by Vam2/6p, and triggered by the action of
Sec18p and Sec17p. It will certainly be important to study
the pathway and regulation of 65S complex assembly.
Vam2/6p fulfills the definition of a Rab effector, yet it as-
sociates with a cis-SNARE complex upstream of its trans-
fer to Ypt7p. The action of Sec18p and Sec17p is required
for this transfer, providing the first functional evidence
linking the priming factors with Rab/Ypt GTPases and
their effectors. It will be important to determine whether
the association of Rab effectors with their cognate
SNAREs in other systems is with cis- or trans-SNARE
complexes and whether it occurs before or after Rab asso-
ciation.
Vam2/6p functions on the vacuole with the Rab GTPase
Ypt7p as a site-specific element for docking. It is, in this
regard, functionally analogous to the plasma membrane–
localized exocyst complex in yeast and mammals (Bowser
et al., 1992; TerBush et al., 1996; Kee et al., 1997; Finger et al.,
1998; Grindstaff et al., 1998), the cis-Golgi–localized
transport protein particle (TRAPP) complex in yeast
(Sacher et al., 1998), and early endosomal autoantigen 1
(EEA1) proteins in homotypic endosome–endosome fu-
sion (Stenmark et al., 1995; Christoforidis et al., 1999;
McBride et al., 1999). In addition, we propose that it func-
tions as a link between priming and docking and suggest
that other Rab/Ypt effectors may also fulfill these func-
tions. Indeed, these complexes share a number of features.
Like the TRAPP and exocyst complexes purified from cy-
tosol (Bowser and Novick, 1988; Sacher et al., 1998), the
soluble Vam2/6p complex released by Gdi1p migrates at
 
z
 
20 S by gradient sedimentation (our unpublished data).
We have shown biochemical interactions between the
Vam2/6p complex, the SNAREs, and Ypt7p, whereas the
TRAPP and exocyst complexes have been shown to inter-
act genetically with homologous factors (Bowser et al.,
1992; Sacher et al., 1998). The Rab5p effector EEA1 can
also interact with NSF and with syntaxin 6, and with com-
plexes containing syntaxin 13 (McBride et al., 1999; Simon-
sen et al., 1999), and thus there may be similarities to the
functions of EEA1 and Vam2/6p. The yeast exocyst com-
ponent Sec15p has also been shown to function with the
plasma membrane Rab GTPase Sec4p (Guo et al., 1999),
and Cao et al. (1998) have shown that the activity of Ypt1p
is required for the proper localization of Uso1p to the cis-
Golgi membrane in yeast. Like components of the TRAPP
and exocyst complexes, Vam2p has homologues in other
organisms, including worms, flies, plants, and mammals
(Nakamura et al., 1997; Radisky et al., 1997; Warner et al.,
1998). Significantly, the 
 
light
 
 gene product, the 
 
Drosophila
VAM2
 
 homologue, plays a role in protein trafficking to
pigment granules, specialized lysosomes in the 
 
Drosophila
 
eye, suggesting a conserved mode of action in lysosome
biogenesis (Warner et al., 1998; Lloyd et al., 1998).
We are only beginning to learn the full structural and
functional complexity of the cis-SNARE complex. The
core of this and other SNARE complexes is undoubtedly
composed of a four-helix bundle (Katz et al., 1998; Poir-
ier et al., 1998; Sutton et al., 1998) with a t-SNARE,
v-SNARE, and s-SNARE. However, these core elements
may be insufficient for function. The vacuole 65S complex
contains the cis-SNARE complex, consisting of Vam3p,
Vam7p, Nyv1p, Vti1p, Ykt6p, Sec17p, Sec18p, and LMA1,
and Vam2/6p itself contains additional subunits (Seals, D.,
G. Eitzen, W. Wickner, and A. Price, manuscript in prepa-
ration). Thus far, these multiple subunits do not appear to
be redundant, as deletion or antibody inhibition of each of
them (after priming, when the constituent subunits are
separated from one another) has a major deleterious ef-
fect on the reaction (Nichols et al., 1997; Ungermann and
Wickner, 1998; Ungermann et al., 1999). We find a smaller
percent of SNAREs in complex with Vam2/6p (Fig. 3 B)
than the percent of Vam2/6p that is associated with
SNAREs (Fig. 3 D), suggesting that there are extra cis-
SNARE complexes without Vam2/6p. This fits with the
observation that trans-SNARE complexes, which need
Vam2/6p to form, only encompass a small percent of the
SNAREs (Ungermann et al., 1998b), and with observa-
tions in other systems such as yeast plasma membrane
t-SNAREs being all over the bud rather than exclusively
at the fusion site at the bud tip (Brennwald et al., 1994),
and in neurons where t-SNAREs are not exclusively at the
synapse (Garcia et al., 1995). Vam2/6p is localized in vivo
to one or two discrete spots per vacuole (Nakamura et al.,
1997), suggesting that like the exocyst on the plasma mem-
brane, the localization of this complex determines the site
of membrane docking. Critical testing of these ideas must
await the determination of whether the same SNAREs
that are in complex with Vam2/6p are those that form the
trans-SNARE pairs.
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